Wednesday, November 16, 2022 3:09:04 PM
$BIXT NEWS - Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in @medrxivpreprint - https://t.co/hEr98kHKRr #gylcotime #galectin #galectin3 #COVID19 #antivirals #longcovid @ChilesResearch @EricTopol @drbeen_medical @EnemyInAState @DrEricDing pic.twitter.com/UopYZdCx5F
— Bioxytran Inc. (@BioxytranInc) November 16, 2022
Major value inflection point for $BIXT like in 2013 when $GILD announced P2 #HCV trial and 19/19 responded. A perfectly designed clinical trial led to HCV cure. #Bioxtran #COVID19 trial 17/17 responders. Major advancement in #Galectin Science & #Glycobiology #Glycovirology pic.twitter.com/ma7T9tDTWr
— Mike Sheikh (@MikeSheikh2) November 16, 2022
Recent BIXT News
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
